Skip to menu Skip to content Skip to footer

A phase 3 open-label study of the safety and efficacy of Adalimumab in subjects with moderate to severe Hidradenitis Suppurativa (2013-2016)

Experts

Professor Peter Soyer

Interim Director, Frazer Institute
Faculty of Medicine
Peter Soyer
Peter Soyer

Associate Professor Erin McMeniman

Principal Research Fellow
Frazer Institute
Faculty of Medicine
ATH - Associate Professor
PA Southside Clinical Unit
Faculty of Medicine
Erin McMeniman